GENIUS SPORTS LTD (GENI) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:GENI • GG00BMF1JR16

8.54 USD
+0.32 (+3.89%)
At close: Feb 4, 2026
8.54 USD
0 (0%)
After Hours: 2/4/2026, 8:04:00 PM
Fundamental Rating

4

Taking everything into account, GENI scores 4 out of 10 in our fundamental rating. GENI was compared to 132 industry peers in the Hotels, Restaurants & Leisure industry. While GENI has a great health rating, there are worries on its profitability. GENI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year GENI has reported negative net income.
  • In the past year GENI had a positive cash flow from operations.
  • In the past 5 years GENI always reported negative net income.
  • In multiple years GENI reported negative operating cash flow during the last 5 years.
GENI Yearly Net Income VS EBIT VS OCF VS FCFGENI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

  • GENI has a Return On Assets of -11.36%. This is amonst the worse of the industry: GENI underperforms 84.09% of its industry peers.
  • GENI's Return On Equity of -16.49% is in line compared to the rest of the industry. GENI outperforms 42.42% of its industry peers.
Industry RankSector Rank
ROA -11.36%
ROE -16.49%
ROIC N/A
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
GENI Yearly ROA, ROE, ROICGENI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • With a Gross Margin value of 21.98%, GENI is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
  • GENI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENI Yearly Profit, Operating, Gross MarginsGENI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

7

2. Health

2.1 Basic Checks

  • GENI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GENI has more shares outstanding
  • GENI has a better debt/assets ratio than last year.
GENI Yearly Shares OutstandingGENI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M 200M
GENI Yearly Total Debt VS Total AssetsGENI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 2.65 indicates that GENI is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.65, GENI is doing good in the industry, outperforming 71.21% of the companies in the same industry.
  • GENI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 2.65
ROIC/WACCN/A
WACC9.36%
GENI Yearly LT Debt VS Equity VS FCFGENI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • GENI has a Current Ratio of 1.73. This is a normal value and indicates that GENI is financially healthy and should not expect problems in meeting its short term obligations.
  • GENI has a Current ratio of 1.73. This is in the better half of the industry: GENI outperforms 77.27% of its industry peers.
  • A Quick Ratio of 1.73 indicates that GENI should not have too much problems paying its short term obligations.
  • GENI has a better Quick ratio (1.73) than 80.30% of its industry peers.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
GENI Yearly Current Assets VS Current LiabilitesGENI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

  • The earnings per share for GENI have decreased strongly by -74.07% in the last year.
  • The Revenue has grown by 30.70% in the past year. This is a very strong growth!
  • The Revenue has been growing by 24.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-74.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320%
Revenue 1Y (TTM)30.7%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%38.34%

3.2 Future

  • Based on estimates for the next years, GENI will show a very strong growth in Earnings Per Share. The EPS will grow by 45.32% on average per year.
  • Based on estimates for the next years, GENI will show a quite strong growth in Revenue. The Revenue will grow by 19.37% on average per year.
EPS Next Y-22.02%
EPS Next 2Y52.42%
EPS Next 3Y45.32%
EPS Next 5YN/A
Revenue Next Year28.4%
Revenue Next 2Y24.26%
Revenue Next 3Y23.33%
Revenue Next 5Y19.37%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GENI Yearly Revenue VS EstimatesGENI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
GENI Yearly EPS VS EstimatesGENI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • GENI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 97.89, the valuation of GENI can be described as expensive.
  • GENI's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. GENI is more expensive than 63.64% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of GENI to the average of the S&P500 Index (27.50), we can say GENI is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 97.89
GENI Price Earnings VS Forward Price EarningsGENI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GENI indicates a slightly more expensive valuation: GENI is more expensive than 60.61% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 372.91
EV/EBITDA N/A
GENI Per share dataGENI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • GENI's earnings are expected to grow with 45.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.42%
EPS Next 3Y45.32%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for GENI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GENIUS SPORTS LTD

NYSE:GENI (2/4/2026, 8:04:00 PM)

After market: 8.54 0 (0%)

8.54

+0.32 (+3.89%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-04
Earnings (Next)03-02
Inst Owners95.69%
Inst Owner Change0.6%
Ins Owners8.07%
Ins Owner ChangeN/A
Market Cap2.16B
Revenue(TTM)604.52M
Net Income(TTM)-119.17M
Analysts82.4
Price Target15.92 (86.42%)
Short Float %7.62%
Short Ratio3.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1971.5%
Min EPS beat(2)-2756.23%
Max EPS beat(2)-1186.76%
EPS beat(4)1
Avg EPS beat(4)-1235.77%
Min EPS beat(4)-2756.23%
Max EPS beat(4)16.89%
EPS beat(8)2
Avg EPS beat(8)-583.76%
EPS beat(12)2
Avg EPS beat(12)-433.97%
EPS beat(16)4
Avg EPS beat(16)-321.65%
Revenue beat(2)1
Avg Revenue beat(2)1.03%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)3.82%
Revenue beat(4)1
Avg Revenue beat(4)-0.48%
Min Revenue beat(4)-2.01%
Max Revenue beat(4)3.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.53%
Revenue beat(12)4
Avg Revenue beat(12)0.29%
Revenue beat(16)7
Avg Revenue beat(16)1.27%
PT rev (1m)2.5%
PT rev (3m)4.04%
EPS NQ rev (1m)-11.23%
EPS NQ rev (3m)-14.11%
EPS NY rev (1m)-5.98%
EPS NY rev (3m)-75.1%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)1.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 97.89
P/S 3.58
P/FCF 372.91
P/OCF 25.72
P/B 2.99
P/tB 9.21
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)0.09
Fwd EY1.02%
FCF(TTM)0.02
FCFY0.27%
OCF(TTM)0.33
OCFY3.89%
SpS2.39
BVpS2.85
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.36%
ROE -16.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.98%
FCFM 0.96%
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 118.97%
Cap/Sales 12.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z 2.65
F-Score5
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)73.83%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320%
EPS Next Y-22.02%
EPS Next 2Y52.42%
EPS Next 3Y45.32%
EPS Next 5YN/A
Revenue 1Y (TTM)30.7%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%38.34%
Revenue Next Year28.4%
Revenue Next 2Y24.26%
Revenue Next 3Y23.33%
Revenue Next 5Y19.37%
EBIT growth 1Y-55.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year385.62%
EBIT Next 3Y93.39%
EBIT Next 5Y57.85%
FCF growth 1Y110.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1224.02%
OCF growth 3YN/A
OCF growth 5YN/A

GENIUS SPORTS LTD / GENI FAQ

What is the ChartMill fundamental rating of GENIUS SPORTS LTD (GENI) stock?

ChartMill assigns a fundamental rating of 4 / 10 to GENI.


What is the valuation status for GENI stock?

ChartMill assigns a valuation rating of 1 / 10 to GENIUS SPORTS LTD (GENI). This can be considered as Overvalued.


How profitable is GENIUS SPORTS LTD (GENI) stock?

GENIUS SPORTS LTD (GENI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for GENI stock?

The Earnings per Share (EPS) of GENIUS SPORTS LTD (GENI) is expected to decline by -22.02% in the next year.